Based on recent research and analysis of the generic drug market, as well as the study and evaluation of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as Frost & Sullivan) has awarded the 'China Generic Drug Leader Award' to Lijing Pharmaceutical (Xiamen) Co., Ltd. (hereinafter referred to as 'Lijing Pharmaceutical'). The award was presented by Dr. Wang Xin, a global partner of Frost & Sullivan and Chairman of the Greater China Region, to Mr. Zhu Haijian, General Manager of Lijing Pharmaceutical (Xiamen) Co., Ltd.
Frost & Sullivan accredits Lipeng Pharmaceutical (Xiamen) Co., Ltd.
"China's Innovative New Drug Leadership Award"
Dr. Wang Xin presented the award to Mr. Zhu Haijian, General Manager of Lipint Pharmaceutical.
Lipint Pharmaceutical is a leading domestic company in the development of improved new drugs
Lipine Pharmaceutical was established in 2012 as an innovative biopharmaceutical company driven by independent research and development and industrialization. It focuses on the development of innovative formulations with high technical barriers such as oral film agents, gas microspheres, and sustained-release preparations. Currently, the company has launched 5 products on the market, including microsphere ultrasound contrast agents and sustained-release preparations, and possesses multiple core innovation technology platforms.
The core technology platform aids in the development of improved new drugs, and independent innovation breaks international monopolies.
Lipintech Pharmaceutical has established four core technology platforms with independent intellectual property rights, including an innovative oral mucosal delivery system technology platform, a gas microsphere technology platform, a sustained and controlled release formulation technology platform, and a technology platform for solubilizing insoluble drugs. These four technology platforms can meet a variety of clinical needs, including solving problems such as efficient drug penetration and absorption, reducing adverse reactions, and enhancing therapeutic effects. The technologies of these four platforms can effectively support the company's entire process of drug research and development project establishment, formulation development, preclinical research, clinical trials, and registration applications during the new drug development process. At the same time, the innovative gas microsphere technology established by Lipintech Pharmaceutical has achieved large-scale production of gas microspheres, breaking the monopoly of foreign enterprises on this technology. With the support of the independent intellectual property platform, Lipintech Pharmaceutical is expected to launch more improved new drugs to further meet clinical needs.
Independent innovation drives clinical development, and core technologies enable multiple drugs to enter clinical trials
Based on the four established technology platforms, Liptech Pharmaceuticals has not only promoted the launch of several improved new drugs but also has several drugs based on these platforms entering clinical trials, including:
1) Innovative oral mucosal delivery system technology platform: LP035 buccal film for treating nausea and vomiting caused by chemotherapy, LP067 buccal film for treating sleep maintenance difficulties, LP074 oral dissolving film for treating erectile dysfunction, and LP072 oral dissolving film for treating Alzheimer's dementia;
2) Gas Microsphere Technology Platform: For the injection of perfluoropropane human serum albumin microspheres used in hysterosalpingography and thyroid ultrasound contrast agents;
3) Sustained-Release and Controlled-Release Preparation Technology Platform: LP106 long-acting injection for the treatment of attention deficit hyperactivity disorder.
The technology platform built by the company has promoted the launch of multiple products and several product pipelines have entered clinical trials. With the subsequent launch of improved new drug products, there is potential to further expand the market and drive industry development.
About the Frost & Sullivan Life Sciences New Investment Summit
The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27-28th, themed 'New Directions for the Future & Moving Forward with Determination'. It brought together more than 30 industry leaders, life science companies, investment institutions, and professional service providers to focus on new opportunities in life sciences investment and financing, and to jointly discuss the capital and industrial forces that enable enterprises to navigate through cycles.
About the Frost & Sullivan China Leadership Award
The Frost & Sullivan China Leadership Award recognizes outstanding performance and achievements in technology innovation, market potential, customer service, brand, and other aspects by enterprises. The Frost & Sullivan team nominated a competitive group of excellent companies to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. An independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs conducted a rigorous review of the companies nominated by the Frost & Sullivan team and decided to award the 'China Innovative New Drug Leadership Award' to Lepin Pharmaceutical (Xiamen) Co., Ltd.
